Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Pearce IP BioBlast®: w/e 11 June 2021

by , | Jun 15, 2021

07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada.  Remsima SC® is indicated for the treatment of rheumatoid arthritis.

07 Jun 21 | Merck released new data on Keytruda® (pembrolizumab) in combination with Lenvima® (levatinib) versus sunitinib in patients with advanced renal cancer. Merck said that the results reinforced the combination of pembrolizumab and levatinib as a potential new treatment option for renal cancer.

08 Jun 21 | Bio-Thera announced it has initiated Ph III trials of BAT2506 (golimumab biosimilar).

09 Jun 21 | Magellan Rx Management announced that its oncology biosimilar medical benefit drug management solution has saved customers over $40 million, with greater savings expected as the market shift to biosimilars accelerates.

10 Jun 21 | Theramex UK announced it has entered into an agreement with Enzene Biosciences for the commercialisation of a biosimilar denosumab. Under the agreement, Enzene will supply Theramex with the product for commercialisation in Europe, the UK, Switzerland and Australia.

Did you know that you can subscribe to Pearce IP’s updates including our weekly BioBlast® and regular pharma and IP industry news? Click here to receive these updates directly in your inbox.

 

 

 

 

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News